Skip to main content

FDA Approvals

FDA Approvals
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
Read More
FDA Approvals
Lemtrada (Alemtuzumab) a New Treatment Option Approved by the FDA for the Treatment of Relapsing Forms of Multiple Sclerosis
Loretta Fala
Read More
FDA Approvals
Farydak (Panobinostat): First HDAC Inhibitor Approved for the Treatment of Patients with Relapsed Multiple Myeloma
Lisa A. Raedler, PhD, RPh
Read More
FDA Approvals
The 2015 Oncology Drug Pipeline: Innovation Drives the Race to Cure Cancer
Dalia Buffery, MA, ABD
Read More
FDA Approvals
Recent FDA Approvals
Read More
FDA Approvals
The Hematology Pipeline Is Abundant
Wayne Kuznar, Kate Smith
Read More
FDA Approvals, Payers' Guide
The Sixth Annual Payers’ Guide to New FDA Approvals
Read More
Payers' Guide, FDA Approvals
FDA Approvals of Brand-Name Prescription Drugs in 2014
Read More
Payers' Guide, FDA Approvals
Afrezza (Insulin Human) Inhalation Powder Approved for the Treatment of Patients with Type 1 or Type 2 Diabetes
Loretta Fala
Read More
Payers' Guide, FDA Approvals
Akynzeo (Netupitant and Palonosetron), a Dual-Acting Oral Agent, Approved by the FDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Lisa A. Raedler, PhD, RPh
Read More
Page 41 of 53
Results 401 - 410 of 525